Protalix BioTherapeutics, Inc. PLX NYSE

Protalix BioTherapeutics, Inc. (PLX) reported total assets of $82.35M and total liabilities of $34.12M for quarter ending 2025-12-31, resulting in total equity of $48.23M.

The company held $30.98M in cash and short-term investments. Total debt stood at $8.32M, with net debt of $-6.36M. The Debt-to-Equity (D/E) ratio was 0.17 (conservative).

Current ratio is 2.51, indicating strong short-term liquidity. Interest coverage is -21x (weak).

Criteria supported by this page:

• HEALTH (67/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (28/100) — Total assets $82.35M and equity $48.23M support the company's competitive scale
• VALUE (100/100) — Debt-to-Equity 0.17 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 53/100 with 2/7 criteria passed.